Zyversa Therapeutics Inc ZVSA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
5.37quote price arrow up+0.09 (+1.70%)
Volume
59,739
52 week range
4.44 - 203.00
Loading...
  • Open5.18
  • Day High5.44
  • Day Low5.16
  • Prev Close5.28
  • 52 Week High203.00
  • 52 Week High Date05/10/23
  • 52 Week Low4.44
  • 52 Week Low Date04/26/24

Key Stats

  • Market Cap4.078M
  • Shares Out759,490.01
  • 10 Day Average Volume1.05M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-40.33

KEY STATS

  • Open5.18
  • Day High5.44
  • Day Low5.16
  • Prev Close5.28
  • 52 Week High203.00
  • 52 Week High Date05/10/23
  • 52 Week Low4.44
  • 52 Week Low Date04/26/24
  • Market Cap4.078M
  • Shares Out759,490.01
  • 10 Day Average Volume1.05M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-40.33

RATIOS/PROFITABILITY

  • EPS (TTM)-1,923.42
  • P/E (TTM)-0.00
  • Fwd P/E (NTM)-0.35
  • EBITDA (TTM)-14.41M
  • ROE (TTM)-191.32%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/19/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Zyversa Therapeutics Inc

 

Profile

MORE
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized...
Stephen Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Peter Wolfe
Chief Financial Officer, Secretary
Address
2200 N. Commerce Parkway, Suite 208
Weston, FL
33326
United States